Impact of Treatment-Related Cardiac Toxicity on Lymphoma Survivors: An Institutional Approach for Risk Reduction and Management

Michele C. Walsh

routine cardiac monitoring, risk reduction, lymphoma, survivors
CJON 2010, 14(4), 505-507. DOI: 10.1188/10.CJON.505-507

Despite improvements in treatment and overall survival rates, survivors of lymphoma may have long-term and late effects. Given the immense risk for cardiac disease after treatment for Hodgkin lymphoma and non-Hodgkin lymphoma, healthcare providers should focus on prevention of secondary adverse effects. The Dana-Farber Cancer Institute has been working to develop guidelines to address the cardiotoxicities that impact the lymphoma survivor population.

Members Only
Not a current ONS member or journal subscriber?

Purchase This Article

Receive a PDF to download and print.